Market Overview:
The global anti-hypertensive drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of hypertension, rising geriatric population, and growing awareness about hypertension and its treatment options. Based on type, the diuretics segment is expected to account for the largest share of the global anti-hypertensive drugs market in 2018. This segment is also projected to grow at the highest CAGR during the forecast period. The large share and high growth rate of this segment can be attributed to factors such as their low cost and wide availability. Based on application, hospital pharmacies are expected to account for the largest share of the global anti-hypertensive drugs market in 2018.
Product Definition:
A drug that reduces blood pressure is called an anti-hypertensive drug. These drugs are important because high blood pressure can damage the heart, kidneys, and other organs.
Diuretics:
Diuretics are substances that increase urine production by inhibiting the renal tubules. Diuretics can be divided into two major groups, loop or non-loop diuretics. Loop diuretic is a class of drugs that works by increasing the amount of sodium excreted through the kidneys in urine. The mechanism behind this type of action is not fully understood but it has been found to reduce blood pressure in humans and experimental animals with hypertension (high blood pressure).
Angiotensin Converting Enzyme (ACE) Inhibitors:
The angiotensin II type 1 receptor (AT1R) is the target of anti-hypertensive drugs. The body’s natural response to high blood pressure is to lower it by reducing the amount of blood pumped out by the heart. However, with continued exposure to high BP levels, the receptors become desensitized and need another approach for hypertension control.
Application Insights:
Based on the application, the global anti-hypertensive drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy held the largest share of over 60.0% in 2017 owing to its usage in treating life-threatening heart conditions such as heart attack and stroke. Furthermore, increasing prevalence of target diseases such as hypertension along with favorable reimbursement policies for medicines consumed in hospitals will drive growth during the forecast period.
The online pharmacy segment is anticipated to witness lucrative growth during the forecast period due to rising awareness about treatment options among a large patient base that prefers self-treatment at home using internet facilities rather than going to a medical facility or pharmacist for purchasing medicines especially pertaining to hypertension medications.
Regional Analysis:
North America dominated the global market in 2017. High prevalence of hypertension, rising geriatric population, and increasing awareness about lifestyle changes are key factors responsible for its growth. Moreover, the presence of major players such as Merck & Co., Inc.; Johnson & Johnson; Pfizer Inc.; Bristol-Myers Squibb Company; and Sanofi is expected to drive regional growth over the forecast period.
Asia Pacific anti-hypertensive drugs market is anticipated to witness lucrative CAGR during the forecast period owing to high unmet clinical needs coupled with rapidly improving healthcare infrastructure in emerging countries such as China and India. Furthermore, growing disposable income levels among middle class groups will boost demand further over this period.
Growth Factors:
- Increasing prevalence of hypertension: The global prevalence of hypertension was estimated to be around 1.13 billion in 2015 and is projected to reach 1.56 billion by 2025, owing to the increasing aging population and rising obesity rates. This will create a large pool of patients who would require anti-hypertensive drugs for treatment, thereby driving the market growth.
- Technological advancements in drug delivery systems: Drug delivery systems are witnessing technological advancements that are making them more efficient and user-friendly. This is resulting in increased adoption of these systems, which is propelling the growth of the anti-hypertensive drugs market. For instance, self-injection devices have gained popularity over traditional injection methods as they offer ease of use and reduce pain during administration.
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti-Hypertensive Drugs Market Research Report
By Type
Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Beta Blockers, Alpha Blockers, Vasodilators, Renin Inhibitors
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Novartis, Pfizer, Johnson & Johnson, Sanofi, Lupin, Ranbaxy Laboratories, Merck, AstraZeneca, Daiichi Sankyo Company Limited, Takeda Pharmaceutical, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
215
Number of Tables & Figures
151
Customization Available
Yes, the report can be customized as per your need.
Global Anti-Hypertensive Drugs Market Report Segments:
The global Anti-Hypertensive Drugs market is segmented on the basis of:
Types
Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Beta Blockers, Alpha Blockers, Vasodilators, Renin Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Pfizer
- Johnson & Johnson
- Sanofi
- Lupin
- Ranbaxy Laboratories
- Merck
- AstraZeneca
- Daiichi Sankyo Company Limited
- Takeda Pharmaceutical
- Novartis
Highlights of The Anti-Hypertensive Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Diuretics
- Angiotensin Converting Enzyme (ACE) Inhibitors
- Angiotensin Receptor Blockers (ARBs)
- Calcium Channel Blockers
- Beta Blockers
- Alpha Blockers
- Vasodilators
- Renin Inhibitors
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-Hypertensive Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anti-hypertensive drugs are medications that help lower blood pressure.
Some of the major players in the anti-hypertensive drugs market are Novartis, Pfizer, Johnson & Johnson, Sanofi, Lupin, Ranbaxy Laboratories, Merck, AstraZeneca, Daiichi Sankyo Company Limited, Takeda Pharmaceutical, Novartis.
The anti-hypertensive drugs market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anti-Hypertensive Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anti-Hypertensive Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anti-Hypertensive Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anti-Hypertensive Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anti-Hypertensive Drugs Market Size & Forecast, 2020-2028
4.5.1 Anti-Hypertensive Drugs Market Size and Y-o-Y Growth
4.5.2 Anti-Hypertensive Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Diuretics
5.2.2 Angiotensin Converting Enzyme (ACE) Inhibitors
5.2.3 Angiotensin Receptor Blockers (ARBs)
5.2.4 Calcium Channel Blockers
5.2.5 Beta Blockers
5.2.6 Alpha Blockers
5.2.7 Vasodilators
5.2.8 Renin Inhibitors
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Anti-Hypertensive Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anti-Hypertensive Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Diuretics
9.6.2 Angiotensin Converting Enzyme (ACE) Inhibitors
9.6.3 Angiotensin Receptor Blockers (ARBs)
9.6.4 Calcium Channel Blockers
9.6.5 Beta Blockers
9.6.6 Alpha Blockers
9.6.7 Vasodilators
9.6.8 Renin Inhibitors
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Diuretics
10.6.2 Angiotensin Converting Enzyme (ACE) Inhibitors
10.6.3 Angiotensin Receptor Blockers (ARBs)
10.6.4 Calcium Channel Blockers
10.6.5 Beta Blockers
10.6.6 Alpha Blockers
10.6.7 Vasodilators
10.6.8 Renin Inhibitors
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Diuretics
11.6.2 Angiotensin Converting Enzyme (ACE) Inhibitors
11.6.3 Angiotensin Receptor Blockers (ARBs)
11.6.4 Calcium Channel Blockers
11.6.5 Beta Blockers
11.6.6 Alpha Blockers
11.6.7 Vasodilators
11.6.8 Renin Inhibitors
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Diuretics
12.6.2 Angiotensin Converting Enzyme (ACE) Inhibitors
12.6.3 Angiotensin Receptor Blockers (ARBs)
12.6.4 Calcium Channel Blockers
12.6.5 Beta Blockers
12.6.6 Alpha Blockers
12.6.7 Vasodilators
12.6.8 Renin Inhibitors
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Diuretics
13.6.2 Angiotensin Converting Enzyme (ACE) Inhibitors
13.6.3 Angiotensin Receptor Blockers (ARBs)
13.6.4 Calcium Channel Blockers
13.6.5 Beta Blockers
13.6.6 Alpha Blockers
13.6.7 Vasodilators
13.6.8 Renin Inhibitors
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Anti-Hypertensive Drugs Market: Competitive Dashboard
14.2 Global Anti-Hypertensive Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Pfizer
14.3.3 Johnson & Johnson
14.3.4 Sanofi
14.3.5 Lupin
14.3.6 Ranbaxy Laboratories
14.3.7 Merck
14.3.8 AstraZeneca
14.3.9 Daiichi Sankyo Company Limited
14.3.10 Takeda Pharmaceutical
14.3.11 Novartis
